MissionIR Articles
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Stand Distinct, Push Brand
Lexaria Bioscience Corp. (NASDAQ: LEXX) acknowledges consumers’ shift away from smoking cigarettes to nicotine alternatives, which has resulted in the growth of the nicotine pouch and nicotine replacement therapy (“NRT”) markets. Through its patented DehydraTECH…
-
New Agreements Signed Between Lexaria Bioscience Corp. (NASDAQ: LEXX) and BevNology LLC; Pre-IND Meeting Request Filed with FDA
The two companies signed a manufacturing operating agreement and a commercial agreement Lexaria sent a pre-IND meeting request letter to the US FDA and plans to file the full IND application in late 2022/early 2023…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Reach of its Drug Delivery Technology Through Newly Inked Agreements with Beverage Developer BevNology
Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants Licenses to Three Companies for the Month of June; Looks to Follow Through with its Scheduled 2022 Clinical Studies
Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD products Valcon Medical A/S also signed an agreement with Lexaria to use its platform for…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today reported recent business highlights and audited financial results for its fiscal year ended March 31, 2022. In addition, the…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the signing of two agreements with Atlanta-based BevNology LLC. According to the update, the first manufacturing operating agreement expands production capabilities…
-
Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions
Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions Lexaria’s patented DehydraTECH solution transforms a…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Ground-Breaking Studies Opening ‘Doors Previously Closed to Disruptive New Technology’
Lexaria Bioscience Corp. (NASDAQ: LEXX) understands the shortcomings of orally administered drugs and is developing DehydraTECH(TM), a drug delivery technology that solves challenges such as poor water solubility and membrane permeability, limited absorption and unwanted…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets
Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension The company has been…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) and the Budding Alternative Nicotine Market
The nicotine pouch market is projected to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7% The smokeless tobacco products sector is expected to post a CAGR of…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Takes First Regulatory Step with FDA for Development of DehydraTECH-CBD in Treating Hypertension
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has successfully filed a pre-Investigational New Drug (“IND”) meeting request letter with the U.S. Food and Drug Administration (“FDA”).…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co.…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better
Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodies Lexaria’s patented…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on 2022 Annual Meeting Voting
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a report on its recent 2022 Annual Meeting and the items that were voted on. The meeting was held on May 31, 2022,…
-
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Consistently Enhancing the Oral Administration of Active Pharmaceutical Ingredients
A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM) Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”) Lexaria…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) as It Looks to Tap into Various Markets
Lexaria Bioscience Corp. (NASDAQ: LEXX) has been pushing the boundaries of drug delivery through its patented DehydraTECH(TM) technology, which has evidenced more efficient delivery of active pharmaceutical ingredients (“APIs”) into the bloodstream while also increasing…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Growing Commercial Opportunities
Lexaria is a biotechnology company focused on licensing its proprietary DehydraTECH(TM) technology The DehydraTECH technology has been proven to increase the bioavailability, speed of onset and brain absorption of APIs, and improve customer experiences by…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Waves in the Growing Antiviral Drug Space with its DehydraTECH Technology
Lexaria Bioscience Corp., through its patented DehydraTECH technology, is improving the way many drugs enter the bloodstream In June 2021, the company proved that an antiviral drug enhanced with its technology was effective at inhibiting…
Search Articles
Latest Articles
- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Advancing a Premier North American Copper District
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
- Safe Pro Group Inc. (NASDAQ: SPAI) Advanced AI Patent Protections with Notification Publications in Australia, Israel, and the European Region
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
- MissionIRNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Prices $7 Million Public Offering of Common Stock and Pre-Funded Warrants